Claritev Corp Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Claritev Corporation on November 12, 2025, with the earliest event reported on the same date. The filing details a secondary equity offering involving the sale of shares by existing stockholders rather than the company itself.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity ratios. The transaction described is a secondary offering where the Company did not sell any shares and did not receive any proceeds.
Material Changes and Transaction Details
- Transaction Type: Secondary offering of 1,500,000 shares of Class A Common Stock by affiliates of Hellman & Friedman (Selling Stockholders).
- Offering Price: $51.50 per share to the public.
- Underwriters: Barclays Capital Inc., Guggenheim Securities, LLC, and Wells Fargo Securities, LLC.
- Over-Allotment Option: Underwriters were granted a 30-day option to purchase up to an additional 225,000 shares.
- Closing Date: The Offering closed on November 14, 2025.
- Company Proceeds: $0. The Company received no proceeds from this sale.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. The primary risk disclosed relates to the indemnification obligations where the Company and Selling Stockholders agreed to indemnify Underwriters against certain liabilities. The text notes that the description of the Underwriting Agreement is subject to the full agreement attached as Exhibit 1.1.
Investor Verification Checklist
- Verify the total number of shares sold by the Selling Stockholders, including any shares purchased under the over-allotment option.
- Confirm the identity of the Selling Stockholders (affiliates of Hellman & Friedman) and their remaining ownership percentage post-offering.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific indemnification terms and termination provisions.
- Check subsequent filings for any updates regarding the exercise of the 30-day over-allotment option.